Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • US markets return to all-time high, XJO likely to open at record
    • Market Update

    US markets return to all-time high, XJO likely to open at record

    The XJO is expected to open higher this morning following a renewed rally in the U.S overnight. Their futures have dipped into the red however, and if they remain so during our session, we could see an intraday pullback from our highs. We should retest all-time highs at roughly 7,850 on open. We may have

    Read More
    Public
  • Resonance Health commences collaboration with Micron to tap into Japan’s biopharmaceuticals market
    • News

    Resonance Health commences collaboration with Micron to tap into Japan’s biopharmaceuticals market

    Medical software company Resonance Health (ASX: RHT) is set to target expansion into Japan through a collaboration agreement with medical imaging company Micron Inc in an effort to accelerate its sales growth in the country. Headquartered in Tokyo, Micron specialises in providing medical imaging support services to contract research organisations (CROs) and biopharmaceutical companies globally.

    Read More
    Public
  • Farming biotech in crop genetics and precision agriculture to drive the global Agroscience market
    • News

    Farming biotech in crop genetics and precision agriculture to drive the global Agroscience market

    According to TechSci Research report, “Agroscience Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Agroscience Market stood at USD $35.94 billion in 2022 and is anticipated to grow with a CAGR of 7.12% in the forecast period, 2024-2028. This can be attributed to crop protection innovations. The need for effective

    Read More
    Public
  • Amplia reports results from initial clinical trials of pancreatic cancer drug
    • News

    Amplia reports results from initial clinical trials of pancreatic cancer drug

    Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) is conducting a clinical trial—the ACCENT trial—for pancreatic cancer. The trial will test a new drug called narmafotinib in combination with standard chemotherapy. Narmafotinib targets a protein called FAK (Focal Adhesion Kinase), which is becoming a hot area of research in cancer treatment. Amplia’s drug aims to make

    Read More
    Public
  • Osteopore wins Singapore and Vietnam market approvals to sell ortho products
    • News

    Osteopore wins Singapore and Vietnam market approvals to sell ortho products

    Over 10% of Singaporean adults suffer from knee osteoarthritis, a progressive joint ailment, with a notable rise in cases among individuals aged 40 to 60. As per the Singapore General Hospital (SGH), knee preservation surgeries have doubled from 50 cases in 2020 to about 100 cases in 2021. Similarly, Vietnam experiences a surge in demand

    Read More
    Public
  • UNITH appoints former Microsoft VP to Board after oversubscribed cap raise is scaled back
    • News

    UNITH appoints former Microsoft VP to Board after oversubscribed cap raise is scaled back

    As artificial intelligence (AI) looms as the biggest disrupter to business over the next decade, AI company UNITH (ASX: UNT) has appointed former Microsoft executive Gary Cox to its Board of Directors, a notable move with Microsoft now one of the world’s biggest players in the space.  Cox brings more than 35 years of tech

    Read More
    Public
  • «
  • ‹
  • 100
  • 101
  • 102
  • 103
  • 104
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.